All In Biotech

Drug Trial Radar · NCT00133874

Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo

An Observer-blind, Multicenter, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, Versus Topical 2% Fusidic Acid Cream Applied Three Times Daily for 7 Days in the Treatment Adult and Paediatric Subjects With Impetigo

Last checked: Nov 20, 2026Latest source record: Jan 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 520 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

520

Actual

Start

Apr 2005

Primary completion

Sep 2005

Study completion Sep 2005

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 24, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
All sexes, from 9 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to determine if topical SB-275833 ointment, 1% is as safe and effective as topical sodium fusidate ointment, 2% for the treatment of impetigo in adults and children as young as 9 months of age.

Conditions

  • Skin Infections, Bacterial

Interventions

  • SB-275833 ointment, 1%Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical response assessed at end of therapy visit. Clinical success defined by the need for no additional antibiotic treatment.Time frame: 7 Days

Locations

69 sites in 10 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Winnipeg, Manitoba, Canada

  • GSK Investigational Site

    Winnipeg, Manitoba, Canada

  • GSK Investigational Site

    St. John's, Newfoundland and Labrador, Canada

  • GSK Investigational Site

    Brampton, Ontario, Canada

  • GSK Investigational Site

    Greater Sudbury, Ontario, Canada

  • GSK Investigational Site

    Kitchener, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    San José, Costa Rica

  • GSK Investigational Site

    Anzin, France

  • GSK Investigational Site

    Bersée, France

  • GSK Investigational Site

    Labarth-Sur-Leze, France

  • GSK Investigational Site

    Martigues, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Seraincourt, France

  • GSK Investigational Site

    Vieux-Condé, France

  • GSK Investigational Site

    Augsburg, Bavaria, Germany

  • GSK Investigational Site

    Gilching, Bavaria, Germany

  • GSK Investigational Site

    Munich, Bavaria, Germany

  • GSK Investigational Site

    Munich, Bavaria, Germany

  • GSK Investigational Site

    Mahlow, Brandenburg, Germany

  • GSK Investigational Site

    Duelmen, Lower Saxony, Germany

  • GSK Investigational Site

    Bad Honnef, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Bonn, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Cologne, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Düsseldorf, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Gelsenkirchen, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Kleve-Materborn, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Krefeld, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Mülheim, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Olpe, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Unna, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Wuppertal, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Worms, Rhineland-Palatinate, Germany

  • GSK Investigational Site

    Döbeln, Saxony, Germany

  • GSK Investigational Site

    Dresden, Saxony, Germany

  • GSK Investigational Site

    Reichenbach, Saxony, Germany

  • GSK Investigational Site

    Schmiedeberg, Saxony, Germany

  • GSK Investigational Site

    Kiel, Schleswig-Holstein, Germany

  • GSK Investigational Site

    Kiel, Schleswig-Holstein, Germany

  • GSK Investigational Site

    Preetz, Schleswig-Holstein, Germany

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.